1 Min Read
Dec 18 (Reuters) - Prometic Life Sciences Inc:
* PROMETIC’S PLASMINOGEN (RYPLAZIM) GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF) Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.